Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Safety and Efficacy of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirukumab (Primary)
- Indications Lupus nephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.